[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

Paymentus Holdings, Inc. (PAY) has filed a Form 4 disclosing that its Chairman, President & CEO, Dushyant Sharma, received 1,100,000 Class A RSUs on 07/02/2025 under the company’s 2021 Equity Incentive Plan. Each RSU converts into one share of Class A common stock as it vests. Vesting schedule: one-sixteenth of the award will vest on each quarterly vesting date beginning 15 Aug 2025 (Feb 15, May 15, Aug 15, Nov 15 thereafter), subject to continued service. Following the grant, the reporting person shows 1,100,000 shares owned directly and an additional 1 share held indirectly through Ashigrace LLC, where Sharma holds sole voting and dispositive power. No price was paid for the RSUs, indicating a standard equity-based compensation grant designed to align executive incentives with shareholder value over time.

Positive

• 1,100,000 RSUs granted to the CEO align management incentives with shareholder interests over a four-year vesting period.
• Quarterly vesting beginning 15 Aug 2025 promotes long-term retention of key leadership.

Negative

• The award represents potential future dilution as each RSU converts to a Class A share upon vesting.
• No performance conditions are cited; vesting depends solely on continued service, which may be viewed as less demanding by some investors.

Insights

Securities Analyst

TL;DR: CEO granted 1.1 M RSUs; standard incentive, limited immediate market impact.

The filing records an equity award of 1,100,000 RSUs to CEO Dushyant Sharma. Because the shares vest quarterly over four years, the grant spreads potential dilution and aligns management with long-term performance. No cash changed hands, and the grant price is $0, typical for RSUs. The direct ownership line now reflects the full 1.1 M shares, while a single share remains under Ashigrace LLC. Absent additional share-count context, the award looks routine for a founder-led growth company and should not create immediate trading pressure.

Corporate Governance Expert

TL;DR: Long-dated RSU grant strengthens retention but increases future dilution risk.

The four-year, quarterly vesting cadence signals a deliberate retention mechanism. Tying vesting to continued service incentivizes leadership stability. From a governance lens, the board is employing equity rather than cash compensation, which improves alignment but dilutes shareholders as shares are issued on each vesting date. The filing meets Section 16 reporting requirements, and the solitary indirect share suggests most of Sharma’s new exposure is held personally rather than via an entity. Overall, the disclosure is transparent and within best-practice norms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arkowitz David

(Last) (First) (Middle)

C/O TUHURA BIOSCIENCES, INC.

10500 UNIVERSITY CENTER DR., SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		D(1)(2)		16,571(3)	D	(4)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.28	06/30/2025		D(1)(2)			12,500	(5)	(5)	Common Stock	12,500	$0	0	D
Stock Option (Right to Buy)	$3.28	06/30/2025		D(1)(2)			20,000	(5)	(5)	Common Stock	20,000	$0	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement").

2. This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA.

3. The number of shares of Kineta Common Stock held by the Reporting Person prior to the reported transaction has been updated to include the correct number of shares held by the Reporting Person following the merger between Kineta, Inc. and Yumanity Therapeutics, Inc., which closed on December 16, 2022.

4. At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.

5. At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.

	/s/ Albert W. Vanderlaan, as Attorney-in-Fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did Paymentus CEO Dushyant Sharma receive in the latest Form 4?

The filing reports a grant of 1,100,000 Class A restricted stock units.

When do the newly granted RSUs to PAY’s CEO begin vesting?

Vesting starts on 15 August 2025 and occurs quarterly thereafter.

Was any cash paid for the 1.1 M RSUs disclosed by Paymentus?

No. The transaction price is reported as $0, indicating a compensation grant.

What is the ownership form of the new shares reported by Paymentus’ CEO?

Direct ownership of 1,100,000 shares and indirect ownership of 1 share via Ashigrace LLC.

Does the Form 4 filing indicate whether Dushyant Sharma remains a 10% owner of PAY?

Yes. The form’s relationship box is checked for Director, Officer, and 10% Owner.